Last update 23 Jun 2024

Doxycycline

Last update 23 Jun 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryDoxycycline is a tetracyclin-like broad-spectrum antibiotic that stops bacteria from growing and replicating by inhibiting the synthesis of bacterial proteins. Doxycycline mechanisms by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the ribosome A site. This hinders the production of proteins and ultimately leads to the death of bacterial cells. Doxycycline is widely used to treat respiratory infections, urinary tract infections and sexually transmitted infections caused by bacteria. Its effectiveness, versatility and low cost make it a valuable tool in the fight against infectious diseases.

Drug Type

Small molecule drug

Synonyms

Doxycycline, Doxycycline (USP), Doxycycline hydrate

+ [7]

Target

30S subunit

Mechanism

30S subunit inhibitors(30S ribosomal subunit inhibitors)

Therapeutic Areas

Infectious DiseasesSkin and Musculoskeletal DiseasesNeoplasms+ [2]

Active Indication

RosaceaInfectious DiseasesDermatitis, Atopic+ [1]

Inactive Indication

Neurofibromatoses

Originator Organization

Renovaro, Inc.

Active Organization

Kaifeng Pharmaceutical (Group) Co., Ltd.Galderma Laboratories LPTianjin Intl Joint Academy of Biotechnology & Medicine

+ [2]

Inactive Organization

CollaGenex Pharmaceuticals, Inc.

Renovaro, Inc.Pfizer Laboratories (Pty) Ltd.

Drug Highest PhaseApproved

First Approval Date

US (06 Dec 1967),

Infectious Diseases

Regulation-

Structure

Molecular FormulaC22H26N2O9

InChIKeyXQTWDDCIUJNLTR-CVHRZJFOSA-N

CAS Registry17086-28-1

407

Clinical Trials associated with Doxycycline

NCT06414408 / Not yet recruitingEarly Phase 1IIT

Randomized Directly Observed Therapy Study to Interpret Clinical Trials of Doxy-PEP

Rates of bacterial sexually transmitted infections (STIs) are rising globally, demanding innovative interventions beyond the scope of current efforts to prevent STIs. The United States Doxycycline Post-exposure Prophylaxis (DoxyPEP) Study has demonstrated the efficacy of doxycycline post-exposure prophylaxis (PEP) among men who have sex with men and transgender women; but puzzlingly, doxycycline PEP was found ineffective in cisgender women in the Kenyan doxycycline Post-Exposure Prophylaxis (dPEP) study, with preliminary data suggesting the low medication adherence may explain the null result. By study end, the investigators will have developed adherence measurement methods for doxycycline in hair, blood, and urine, and will use these techniques to help interpret the Kenyan dPEP study, and to examine the relative performance of these methods within the United States DoxyPEP trial, establishing adherence metrics for current and future rollout studies of doxycycline post-exposure prophylaxis

Start Date01 Sep 2024

Sponsor / Collaborator

The University of California, San Francisco

NCT06045481 / Not yet recruitingNot ApplicableIIT

Postexposure Prophylaxis With Single Dose Doxycycline for the Prevention of Tick-borne Relapsing Fever

The goal of this clinical trial is to compare standard treatment (5 days of doxycycline) vs single dose doxycycline for the prevention of tick-borne relapsing fever in soldiers who found bite marks on their bodies after an activity that includes contact with the ground or staying at a site suspected of being infected with ticks. The main question[s] it aims to answer are:
Testing whether preventive treatment with a single dose of doxylin at a dose of 200 mg is effective in preventing recurrent fever, and if so, at what rate
Checking the profile and rate of side effects in each one of the proposed treatment protocols Participants will be treated with standard treatment (5 days of doxycycline) or single dose doxycycline.

Start Date01 Aug 2024

Sponsor / Collaborator-

NCT06468462 / Not yet recruitingPhase 4IIT

WHO-recommended Periodic Presumptive Treatment Versus Doxycycline Post-Exposure Prophylaxis for STI Control Among Cisgender Men Who Have Sex With Men in Kenya

Men who have sex with men (MSM) are at high risk for gonorrhea and chlamydia in Kenya, where nucleic acid amplification testing is not feasible and most infections therefore go undiagnosed. We propose an open-label randomized clinical trial with 2900 participants assigned to WHO-recommended periodic presumptive treatment (PPT) or doxycycline post-exposure prophylaxis (doxyPEP), compared to standard syndromic treatment, with 18 months of follow-up and rigorous culture-based and molecular analysis of antimicrobial resistance in Neisseria gonorrhoeae. This work will provide critical data needed to inform guidelines and improve STI control among MSM in sub-Saharan Africa and other resource-limited settings, including modelled estimates of the health and economic impact of scaling up these two interventions on STI control among MSM and their partners in Kenya.

Start Date01 Aug 2024

Sponsor / Collaborator

University of Washington

[+4]

100 Clinical Results associated with Doxycycline

100 Translational Medicine associated with Doxycycline

100 Patents (Medical) associated with Doxycycline

14,661

Literatures (Medical) associated with Doxycycline

01 May 2024·Ticks and tick-borne diseases

Repeated imidocarb treatment failure suggesting emerging resistance of Babesia canis in a new endemic area in north-eastern Germany

Article

Author: Krücken, Jürgen ; Weingart, Christiane ; Kohn, Barbara

Canine babesiosis has been increasingly diagnosed in various regions of Germany such as north-eastern Germany in recent years. A dog with several relapses of Babesia canis infection after treatment with imidocarb is described. A 9-year-old male Magyar Viszla with B. canis infection was referred after two treatments with imidocarb (dosage 2.1 mg/kg SC) because of lethargy, fever and pancytopenia (additional treatments with prednisolone and doxycycline). Merozoites were detected in the blood smear and imidocarb treatment was repeated. Clinical signs, pancytopenia and a positive B. canis PCR occurred after the 3rd (6 mg/kg SC), 4th (7.7 mg/kg SC) and 5th (7.5 mg/kg SC and doxycycline for 4 weeks in addition) imidocarb injection and thorough tick prevention with isoxazoline and permethrin products. 12 days after the 5th injection, the PCR was negative for the first time. The dog was again presented with fever 35 days after the 5th injection. The B. canis PCR was positive and laboratory examination revealed pancytopenia. Treatment with atovaquone/azithromycin for 18 days was performed and no further relapse occurred for 32 weeks. In the case of suspected imidocarb resistance in B. canis infection, treatment with atovaquone/azithromycin can be an alternative.

01 May 2024·Talanta

Green hairy basil seed mucilage biosorbent for dispersive solid phase extraction enrichment of tetracyclines in bovine milk samples followed by HPLC analysis

Article

Author: Ponhong, Kraingkrai ; Prompila, Nattaya ; Siriangkhawut, Watsaka ; Nakhonchai, Nongnapas ; Vichapong, Jitlada ; Supharoek, Sam-Ang

Unmodified hairy basil seed mucilage (Ocimum basilicum L.), with attractive features as structural functionality and adsorption capacity, was employed as a green biosorbent for dispersive solid phase extraction and enrichment of oxytetracycline, tetracycline, and doxycycline before quantitation by HPLC-UV for the first time. Hairy basil crushed seed increased the contacting surface area and was completely dispersed in the sample solution to extract tetracyclines under acidic condition with the assistance of ultrasonic waves. The analytes in the extraction phase were separated on a C₁₈ column under isocratic condition with a mobile phase consisted of acetonitrile and trifluoroacetic acid. Influence of chemical and physical variables on the extraction efficiency of the developed method was investigated and optimized systematically. Under the optimal condition of all experimental parameters, good linear ranges were obtained at 15.0-500 μg L^-1 for tetracyclines with determination coefficients more than 0.9994. Limits of detection (LODs) and limits of quantitation (LOQs) ranged 5.0-7.0 and 15.0 μg L^-1, respectively. Relative standard deviations (RSDs) of the proposed method at 100 and 300 μg L^-1 for TCs were less than 13 % and 10 %, respectively with percentage TC recoveries from spiked standard ranging 83.1-109.9 %. This simple, reliable, cost-effective, and environmentally friendly method was successfully applied for the analysis of tetracycline residues in milk. The greenness of the proposed method was assessed using the Analytical Eco-Scale and AGREE protocol.

01 Apr 2024·Waste management (New York, N.Y.)

Removal of antibiotic resistance genes during swine manure composting is strongly impaired by high levels of doxycycline residues

Article

Author: Wang, Yan ; Xu, Jiaojiao ; Wu, Yinbao ; Ma, Baohua ; Chen, Majian ; Zhu, Ting ; Zou, Yongde ; Worrich, Anja ; Wen, Xin ; Liao, Xindi

Antibiotic resistance genes (ARGs) are emerging pollutants that enter the farm and surrounding environment via the manure of antibiotic-treated animals. Pretreatment of livestock manure by composting decreases ARGs abundance, but how antibiotic residues affect ARGs removal efficiency remains poorly understood. Here, we explored the fate of the resistome under different doxycycline residue levels during aerobic swine manure composting. Metagenomic sequencing showed that the presence of high levels of doxycycline generally had a higher abundance of tetracycline ARGs, and their dominant host bacteria of Firmicutes, especially Clostridium and Streptococcus, also had limited elimination in composting under high levels of doxycycline stress. Moreover, high levels of doxycycline impaired the removal of the total ARGs number in finished composts, with a removal rate of 51.74 % compared to 63.70 % and 71.52 % for the control and low-level doxycycline manure, respectively. Horizontal gene transfer and strengthened correlations among the bacterial community fostered ARGs preservation at high doxycycline levels during composting. In addition, ARGs carried by both plasmids and chromosomes, such as multidrug ARGs, showed wide host characteristics and rebound during compost maturation. Compared with chromosomes, a greater variety of ARGs on plasmids suggested that the majority of ARGs were characterized by horizontal mobility during composting, and the cross-host characteristics of ARGs during composting deserve further attention. This study provided deep insight into the fate of ARGs under residual antibiotic stress during manure composting and reminded the associated risk for environmental and public health.

News (Medical) associated with Doxycycline

18 Jun 2024

·www.globenewswire.com

PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial

After a Reduction in Surgical Site Infection (SSI) Rates During COVID, Rates are Now Increasing, Signaling a Return to Pre-COVID Levels Known Procedure and Patient Risk-Factors Significantly Increase the Risk of SSIs and Impact Payer Costs Approximately 250 Patients of a Planned Total of 600 Subjects Currently Enrolled in SHIELD II Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in the First Quarter of 2025 PETACH TIKVA, Israel, June 18, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today hosted a virtual Key Opinion Leader event discussing the significant unmet medical need in the prevention of surgical site infections (SSIs). The Company also provided an update on its ongoing SHIELD II Phase 3 trial for D-PLEX100. Charles E. Edmiston, Ph.D. (Emeritus Professor of Surgery, Division of Vascular Surgery, Medical College of Wisconsin), discussed several key topics surrounding SSIs. Key takeaways include: The return to higher pre-COVID SSI rates due to the increase in the number of elective surgeries conducted and the surgical environment normalizing to levels found prior to 2020.SSIs are under-reported, and up to 30-35% of colorectal infections are missed due to sub-optimal surveillance strategies.Procedural and patient-related risk factors such as smoking, alcohol abuse, type 2 diabetes and a high BMI have a significant negative impact on the risk of developing a SSI, and this increase in risk is compounded when patients have multiple risk factors.Long term cost to commercial payers of a single colorectal SSI event over a period of 24 months can range from $44,000 (superficial SSI) to $64,000 (deep SSI), with the cost for Medicare ranging from $20,000 to $45,000, respectively.Surgical care bundles in patients undergoing colorectal surgery significantly reduce the risk of SSIs. The 30-day high concentration release of antibiotics achieved with D-PLEX100 has the potential to add additional benefit to infection prevention bundles. “Studies show traditional evidence-based interventions have maximum benefit within the perioperative and immediate postoperative period. Building upon this, D-PLEX100 supports prolonged doxycycline concentrations within the surgical wound during and beyond this critical period and exceeds the minimum inhibitory concentration for the most common surgical wound pathogens regardless of length of the surgical incision,” said Dr. Edmiston. “There remains an opportunity to improve upon the existing clinical standard of care to reduce the rate of SSIs in and beyond the colorectal surgical setting, improving the patient experience and lowering costs for payers.” PolyPid also provided an update on the enrollment of its ongoing Phase 3 SHIELD II trial of its lead product candidate, D-PLEX100. The SHIELD II clinical study includes patients undergoing abdominal colorectal surgery with large incisions and has now enrolled approximately 250 patients of a planned total of approximately 600 subjects. Approximately 50 centers are currently open and recruiting patients. Top-line results are expected in the first quarter of 2025. The Company intends to conduct an unblinded interim analysis once a total of approximately 400 patients complete their 30-day follow-up, which is anticipated to occur in the fourth quarter of 2024. About SHIELD IISHIELD II (Surgical site Hospital acquired Infection prEvention with Local D-PLEX) is a prospective, multinational, randomized, double blind Phase 3 trial designed to assess the efficacy and safety of D-PLEX100 administered concomitantly with standard of care (SoC), which includes prophylactic systemic antibiotics, compared to SoC alone arm, in the prevention of post abdominal-surgery incisional infection in patients undergoing surgeries with incisions greater than 20 cm. The primary endpoint of the trial is measured by the proportion of subjects with either an SSI event as determined by a blinded and independent adjudication committee, reintervention, or mortality for any reason within 30 days post-surgery. Patient safety will be monitored for an additional 30 days. The trial will enroll patients in centers in the United States, Europe and Israel. About D-PLEX100D-PLEX100, PolyPid’s lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX100 into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for a period of 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. D-PLEX100 received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the prevention of SSIs in patients undergoing elective colorectal surgery. D-PLEX100 is currently in Phase 3 SHIELD II trial for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions. About PolyPidPolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn. Forward-looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses potential benefits and advantages of D-PLEX100, that there remains an opportunity to improve upon the existing clinical standard of care to reduce the rate of SSIs in and beyond the colorectal surgical setting, improving the patient experience and lowering costs for payers, total recruitment time into the study and the timing of the top-line results and an unblinded interim analysis. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed on March 6, 2024. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites. Contacts:PolyPid Ltd. Ori WarshavskyCOO – US908-858-5995IR@Polypid.com Investors:Brian RitchieLifeSci Advisors212-915-2578BRitchie@lifesciadvisors.com

Phase 3Breakthrough Therapy

10 Jun 2024

·www.globenewswire.com

PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company’s Ongoing D-PLEX₁₀₀ Phase 3 Trial

Charles E. Edmiston, Ph.D., Emeritus Professor of Surgery, Medical College of Wisconsin, to discuss the significant unmet medical need in surgical site infections preventionCompany to Provide an Update on SHIELD II Phase 3 Study Enrollment During Event PETACH TIKVA, Israel, June 10, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a virtual Key Opinion Leader (KOL) event on Monday, June 17, 2024, at 10:00 AM ET, to discuss the significant unmet medical need in surgical site infections and provide an update on the Company’s ongoing D-PLEX100 Phase 3 trial. To register, click here. The event will feature Charles E. Edmiston, Ph.D. (Emeritus Professor of Surgery, Division of Vascular Surgery, Medical College of Wisconsin), who will discuss the significant clinical and economic burden, and current medical practice, for the prevention of surgical site infections (SSIs). It will also highlight PolyPid's lead product candidate, D-PLEX100, and its ongoing Phase 3 SHIELD II trial evaluating D-PLEX100 for the prevention of abdominal colorectal SSIs. PolyPid management intends to provide an update on patient enrollment in SHIELD II during the event. A live question and answer session with Professor Edmiston and the Company’s management team will follow the formal presentation. About Charles E. Edmiston, Ph.D. Charles E. Edmiston, Ph.D., is Emeritus Professor of Surgery, at the Medical College of Wisconsin in Milwaukee, Wisconsin, where he also served as Director and Professor, Surgical Microbiology and Hospital Epidemiology Research Laboratory, and Hospital Epidemiologist, Froedtert Hospital. Dr. Edmiston served as Adjunct Professor, Vanderbilt University School of Medicine, Nashville, Tennessee, and SSI Expert Liaison for the State of Wisconsin Division of Public Health. He completed his doctorate at Vanderbilt University in Nashville, Tennessee, joining the Surgical faculty in Milwaukee in 1984 to develop a surgical infectious disease research program. Professor Edmiston is a fellow of the Infectious Disease Society of American, Association of Practitioners in Infection control and Epidemiology, Surgical Infection Society and Society for Healthcare Epidemiology of America. He is board credentialed in both Infection Control (CBIC) and as a Specialist in Clinical Microbiology (ASCP) and has served as a consultant to the U.S. Food and Drug Administration (FDA) as an expert on the infection control implications of implantable biomedical devices, including as Chairman of the General Hospital and Personal Use Device Panel of the Medical Devices Committee of the FDA. Dr. Edmiston has also served as Surgical Infection Society (SIS) liaison to the Hospital Infection Control Practice Advisory Committee (HICPAC) of the Centers for Disease Control and Prevention (CDC). Dr. Edmiston is a current member of two Editorial Boards: Infection Control and Hospital Epidemiology, and Surgical Infections, and a past board member of Surgery, American Journal of Infection Control and JAMA Surgery. His major research interests include intravascular device-related infections, nosocomial risks in the operating room environment, biomedical-device associated infections, impact of selected risk factors for SSIs, perioperative antibiotic prophylaxis, surface disinfection, innovative strategies for reducing the risk of SSIs, molecular epidemiology of SSIs and perioperative antisepsis. Dr. Edmiston is the author of over 400 published peer-reviewed publications including book chapters, editorials reviews, manuals and abstracts, and has delivered over 500 national and international invited lectures/workshops. About SHIELD II SHIELD II (Surgical site Hospital acquired Infection prEvention with Local D-PLEX) is a prospective, multinational, randomized, double blind Phase 3 trial designed to assess the efficacy and safety of D-PLEX100 administered concomitantly with standard of care (SoC), which includes prophylactic systemic antibiotics, compared to SoC alone arm, in the prevention of post abdominal-surgery incisional infection in patients undergoing abdominal colorectal surgeries with large incisions. The primary endpoint of the trial is measured by the proportion of subjects with either a SSI event as determined by a blinded and independent adjudication committee, reintervention, or mortality for any reason within 30 days post-surgery. Patient safety will be monitored for an additional 30 days. The trial will enroll patients in centers in the United States, Europe and Israel. About D-PLEX100 D-PLEX100, PolyPid’s lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX100 into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for a period of 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. D-PLEX100 received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the prevention of SSIs in patients undergoing elective colorectal surgery. D-PLEX100 is currently in Phase 3 SHIELD II trial for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions. About PolyPid PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn. Contacts:PolyPid Ltd. Ori WarshavskyCOO – US908-858-5995IR@Polypid.com Investors:Brian RitchieLifeSci Advisors212-915-2578britchie@lifesciadvisors.com

Phase 3Breakthrough TherapyQualified Infectious Disease Product

06 Jun 2024

·www.fiercepharma.com

CDC recommends antibiotic doxycycline to protect against STIs after potential exposure

For some individuals, the CDC has recommended the use of the antibiotic doxycycline to protect against sexually transmitted diseases (STIs) after instances of potential exposure. Doxycycline, an antibiotic widely used to combat acne, malaria and Lyme disease, has been recommended by the CDC for use in the United States by gay and bisexual men and transgender women after having unprotected sex to ward off sexually transmitted infections (STIs). Post-exposure prophylaxis (PEP) treatment with a 200 mg dose of doxycycline is recommended within 72 hours of having unprotected oral, vaginal or anal sex and comes as infections for syphilis, gonorrhea and chlamydia are on the rise in the U.S., disproportionally affecting men who have sex with men and transgender women. Three trials have shown that post-exposure prophylaxis (PEP) use of doxycycline can reduce the risk of syphilis or gonorrhea infection by more than 70% and chlamydia infection by 50%, the CDC said. Doxycyline comes in pill form and users should limit use to a 200 mg dose over a 24-hour period. The strategy is referred to as doxy PEP and is similar to post-exposure regimens for the prevention of HIV. The CDC recommends that at-risk individuals acquire prescriptions, allowing them to self-administer doxycycline as soon as possible after engaging in unprotected sex. The agency's guidelines say that those who are prescribed doxy PEP should undergo bacterial STI testing and be reassessed every three to six months In 2022, more than 2.51 million cases of syphilis, gonorrhea and chlamydia were reported in the U.S., up from 2.37 million cases in 2017. The rise of syphilis—which was nearly stamped out 20 years ago—has become increasingly troubling, with infections up 79% from 2018 to 2022. Over that period, gonorrhea infections were up 11%.

Drug ApprovalQualified Infectious Disease Product

100 Deals associated with Doxycycline

External Link

KEGG	Wiki	ATC	Drug Bank
D00307	-	-	DB00254

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Rosacea	US	Galderma Laboratories LP	26 May 2006
Infectious Diseases	US	Pfizer Laboratories (Pty) Ltd.	06 Dec 1967

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dermatitis, Atopic	Phase 2	US	Nanopharmaceutics, Inc.Startup	25 Apr 2023
Neurofibromatoses	Phase 2	-	Renovaro, Inc.	-
Advanced Malignant Solid Neoplasm	Phase 1	CN	Kaifeng Pharmaceutical (Group) Co., Ltd.	04 Jul 2019
Advanced Malignant Solid Neoplasm	Phase 1	CN	Tianjin Intl Joint Academy of Biotechnology & Medicine	04 Jul 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02553473 (CTgov)	Phase 3	Lyme Neuroborreliosis	121	Doxycycline (Doxycycline for 6 Weeks)	aljfaoragg(etnfagoaws) = kwlxogcpvh rwocnejquf (tlbclzqszq, efndpphqcd - hhydorslno) View more	-	23 Jan 2024
				Placebo+Doxycycline (Doxycycline for 2 Weeks + Placebo)	aljfaoragg(etnfagoaws) = txyixjmsbg rwocnejquf (tlbclzqszq, ecqqhgqcnv - lcwxsoszmc) View more
WCD2023	Phase 4	Severe acne	198	Combination therapy	zwaoqnyhat(tmvbfmuvhn) = cpvdvmpzxo wdrbryhkqh (tnihnjxzid ) View more	-	03 Jul 2023
NCT02775695 (CTgov)	Phase 2	Pancreatic Cancer	12	Doxycycline	lmtgogzlfl(czndootuqb) = knqmxnuiug iivywrcrml (uzadcxebpr, fodccddouo - ticsqahkin) View more	-	03 Jul 2023
ICML2023	Phase 2	Marginal Zone B-Cell Lymphoma First line	44	Doxycycline 100 mg	xgdbastvts(fxigtxkvsc) = tzjcknjfaa rzolamyjkz (oirmuldhnp, 74 - 77) View more	Positive	09 Jun 2023
ASCO2023	Not Applicable	Hematopoietic stem cell transplantation	341	Fluoroquinolones	lwsjhwhlug(obtyjbptfh) = fethepklui bisgwxigus (uuzsynhczf ) View more	Negative	31 May 2023
				Fluoroquinolones + Doxycycline	lwsjhwhlug(obtyjbptfh) = ydiyrnnrap bisgwxigus (uuzsynhczf ) View more
NCT04860505 (CTgov)	Phase 4	Sexually Transmitted Diseases	20	Doxycycline+Biktarvy	nbjcschtdp(rbwwfzeqtl) = dtsztralxq jepujzkcig (twtnpnqrif, mgjupvqryx - hugllhywai) View more	-	23 May 2023
NCT03479502 (CTgov)	Phase 4	Bursitis	1	Methylprednisolone Injectable Product (Methylprednisolone)	xlafbyqbbr(bhjvplxnek) = nuywurmnlf lylmxvraxj (vgqwbgyffl, asijsyhumz - aohylkggof) View more	-	27 Apr 2023
				Doxycycline Injection (Doxycycline)	xlafbyqbbr(bhjvplxnek) = pyurbjoaxx lylmxvraxj (vgqwbgyffl, cpskksswcz - jgzjqwgukl) View more
NCT03980223 (DoxyPEP, Pubmed)	Phase 4	Sexually Transmitted Diseases, Bacterial	501	Doxycycline postexposure prophylaxis	dnyihbbzcf(atbtoshskb): RR = 0.12 (95% CI, 0.05 - 0.25) View more	Positive	06 Apr 2023
				Standard care without doxycycline
CTRI/2018/08/015159 (Pubmed \| Br Dent J)	Not Applicable	Scrub Typhus	794	Intravenous Doxycycline	wrkfekdyhv(xyspqcungh) = dgtgvjczid ftwylvmgdc (qrzeugjxgi )	Positive	02 Mar 2023
				Azithromycin	wrkfekdyhv(xyspqcungh) = kzptkvqvci ftwylvmgdc (qrzeugjxgi )
IELSG39 (ASH2022) Manual	Phase 2	Familial Primary Gastric Lymphoma First line	44	Doxycycline	ettqaxsnel(yzbblgfjcp) = ddkaeikcuh ncseqcljkw (dvkshywaga, 71 - 73) View more	Positive	15 Nov 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis